Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 5Neoplasms 3Leukemia, Myeloid, Acute 3Ovarian Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Leukemia 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinogenesis 1

Interventions

Carboplatin 42Etoposide 37Cisplatin 23Topotecan 22Nivolumab 17pembrolizumab 12atezolizumab 12Ipilimumab 10Paclitaxel 9durvalumab 8Irinotecan 8Radiosurgery 6Pemetrexed 6rovalpituzumab tesirine 5Magnetic Resonance Spectroscopy 5trioctyl phosphine oxide 4trilaciclib 4etoposide phosphate 4berzosertib 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4Dexamethasone 4veliparib 3tremelimumab 3olaparib 3carfilzomib 3cabozantinib 3Temozolomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Small Cell Lung Carcinoma × Monatide (IMS 3015) × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡